Annals of medicine and surgery (2012) · 2025
IgG4 unveiled: navigating the interplay with Crohn's disease - from immunology insights to machine learning.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohan Anmol, Ghaffar Urooj, Basharat Ahmad, Nawaz Gul, Khenhrani Raja Ram, Rimsha, Vera Guillermo de Jesus Aguirre, Lal Priyanka Mohan, Tanush Dev, Khan Muhammad Khuzzaim, Duseja Nikhil, Sherazi Syeda Laiba, Vikash, Kumar Vikash, Nanavaty Dhairya
Аннотация
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by relapsing-remitting episodes and a progressive course that often leads to bowel damage and disability. While the etiology of CD is multifactorial, involving genetic, environmental, and immunological factors, recent studies have highlighted the role of food antigens and the gut microbiome in its pathogenesis. This paper explores the immunological underpinnings of CD, with a focus on the elevated levels of serum immunoglobulin G4 (IgG4) and their correlation with disease severity and therapeutic response. We review clinical trials and case studies that demonstrate the potential of IgG4-guided exclusion diets and intravenous immunoglobulin (IVIG) therapy in ameliorating CD symptoms and inflammation. Additionally, we delve into advancements in machine learning (ML) models that utilize fecal microbiome data, offering promising diagnostic tools for distinguishing CD from ulcerative colitis and non-IBD conditions. The integration of ML in endoscopy and predictive models for therapy complications signifies a leap toward precision medicine in IBD management. This paper underscores the necessity for a nuanced understanding of CD's immunological aspects and the innovative application of ML in its diagnosis and treatment, paving the way for personalized therapeutic strategies and improved patient outcomes.